Navigation Links
Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020
Date:12/8/2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0332354/Prostate-Cancer---Spain-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020

SummaryGlobalData's pharmaceutical report, "Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the Spanish prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Spanish prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Spanish prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized Spanish prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the Spanish Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Spain.

Reasons to buyThe report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the Spanish prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the Spanish prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the Spanish to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the Spanish prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the Spanish prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Disease Overview 10

2.1 Overview 10

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10

2.1.2 Jewett-Whitmore system 11

2.2 Epidemiology 12

2.3 Etiology 12

2.4 Symptoms 12

2.4.1 Localized or Locally Advanced Prostate Cancer 12

2.4.2 Metastatic Prostate Cancer 13

2.5 Diagnosis 13

2.5.1 Digital Rectal Examination 13

2.5.2 Prostate Specific Antigen Test 14

2.5.3 Transrectal Ultrasound 14

2.5.4 Prostate Biopsy 15

2.6 Pathology 15

2.6.1 Grading 15

2.7 Treatment 15

2.7.1 Watchful Waiting 15

2.7.2 Radiation therapy 16

2.7.3 Surgery 17

2.7.4 Hormone therapy 17

2.7.5 Chemotherapy Options 18

2.7.6 Other Treatments Being Studied 19

2.8 Treatment Guidelines 20

3 Market Characterization 21

3.1 Spain 21

3.1.1 Market Size 21

3.1.2 Drivers and Barriers 27

3.1.3 Impact on the Market 28

3.1.4 Forecasts 29

3.1.5 Drug Sales 36

3.1.6 Pricing and Reimbursements 40

4 Competitor Assessment 41

4.1 Strategic Competitor Assessment 41

4.1.1 Overview 41

4.1.2 Benchmarking 41

4.1.3 Current Competitor Assessment 45

4.2 Launch Analysis and Sales Forecasts 47

4.3 Product Profiles 48

4.3.1 Taxotere (docetaxel) 49

4.3.2 Casodex (Bicalutamide) 53

4.3.3 Zoladex (Goserelin) 59

4.3.4 Eligard (leuprolide acetate) 61

4.3.5 Firmagon (degarelix) 65

4.3.6 Novantrone (Mitoxantrone hydrochloride) 68

4.3.7 Emcyt (estramustine) 70

4.3.8 Trelstar (triptorelin) 72

4.3.9 Eulexin 73

4.3.10 Delestrogen 75

4.3.11 Gynodiol 77

4.3.12 Estrace tablet 78

4.3.13 Tace 79

4.3.14 Nilandrone 80

4.3.15 Premarin 81

4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 82

5 Pipeline Assessment 83

5.1 Overview 83

5.2 Pipeline Analysis by Phase of Development 84

5.3 Pipeline by Mechanism of Action 85

5.4 Strategic Pipeline Assessment 86

5.4.1 Technology Trends Analytical Framework 86

5.5 Trends in Prostate Cancer Pipeline 87

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 87

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 87

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 88

5.6 Partners in Research and Development 88

5.6.1 Licensing Agreements by Phase of Development 89

5.6.2 Licensing Agreements by Geography 92

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 92

5.7 Most Promising Drugs' Profiles 93

5.7.1 Provenge (sipuleucel-T) 95

5.7.2 Jevtana (cabazitaxel) 97

5.7.3 Aflibercept (VEGF Trap) 99

5.7.4 Ipilimumab 101

5.7.5 Abiraterone Acetate (CB7630) 104

5.7.6 Zibotentan (ZD4054) 107

5.7.7 Sprycel (dasatinib) 109

5.7.8 MDV3100 111

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 114

5.9 Prostate Cancer Pipeline – Phase I 116

5.10 Prostate Cancer Pipeline – Phase II 119

5.11 Prostate Cancer Pipeline – Phase III 128

5.12 Key Takeaway 130

6 Unmet Need and Target Product Profile 131

6.1 Unmet Need 133

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 133

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 134

6.2 Opportunity for Target Product 135

6.3 Target Product Profile 138

6.3.1 Ideal Characteristics 138

6.3.2 Target Product Description 139

6.4 Key Takeaway 139

7 Strategic Assessment 140

7.1 Key Events Impacting the Future Market 140

7.2 Market Impact Analysis 141

7.3 Future Market Scenario 141

7.4 Company Analysis 142

7.4.1 Market Leadership 142

7.4.2 Future Players in the Market 143

7.5 Key Takeaway 143

8 Company Profiles 144

8.1 Sanofi-aventis 144

8.1.1 Business Description 144

8.1.2 Financial Overview 146

8.1.3 SWOT Analysis 146

8.1.4 Oncology Focus 151

8.2 Pfizer Inc. 152

8.2.1 Business Description 152

8.2.2 Financial Overview 153

8.2.3 SWOT Analysis 153

8.2.4 Oncology Focus 159

8.3 AstraZeneca 161

8.3.1 Business Description 161

8.3.2 Financial Overview 162

8.3.3 SWOT Analysis 163

8.3.4 Oncology Focus 167

8.4 Bristol-Myers Squibb 169

8.4.1 Business Description 169

8.4.2 Financial Overview 170

8.4.3 SWOT Analysis 170

8.4.4 Oncology Focus 175

8.5 Medivation 177

8.5.1 Business Description 177

8.5.2 SWOT Analysis 177

8.5.3 Oncology Focus 180

8.6 Takeda Pharmaceuticals 180

8.6.1 Business Description 180

8.6.2 SWOT Analysis 181

8.7 Dendreon Corporation 183

8.7.1 Business Description 183

8.7.2 SWOT Analysis 183

8.8 Johnson and Johnson 186

8.8.1 Business Description 186

8.8.2 SWOT Analysis 188

8.8.3 Oncology Focus 194

8.9 Auron Healthcare GmbH 195

8.9.1 Business Description 195

8.10 Oncogenex Pharmaceuticals, Inc. 195

8.10.1 Business Description 195

8.11 Agennix AG 195

8.11.1 Business Description 195

8.12 GTx, Inc. 196

8.12.1 Business Description 196

8.13 GlaxoSmithKline plc. 196

8.13.1 Business Description 196

8.13.2 Financial Overview 197

8.13.3 SWOT Analysis 197

8.13.4 Oncology Focus 203

9 M&A Analysis 205

9.1 Key Highlights 205

9.2 Key Deals' Analysis 207

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 207

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 207

9.2.3 Tolmar Holding Acquires QLT USA from QLT 207

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 207

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 207

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 208

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 208

9.2.8 GPC Biotech Merges with Agennix 208

9.2.9 Eli Lilly Acquires ImClone 208

9.2.10 BBM Holdings Acquires YM BioSciences 208

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 209

9.3 M&A Deals by Geography 209

9.4 M&A Deals by Deal Size 210

10 Expert Opinion 211

10.1 Spain 211

11 Appendix 212

11.1 Market Definitions 212

11.2 Abbreviations 212

11.3 Research Methodology 214

11.3.1 Coverage 215

11.3.2 Secondary Research 215

11.3.3 Forecasting 215

11.3.4 Primary Research 218

11.3.5 Expert Panel validation 218

11.3.6 Contact Us 218

11.3.7 Disclaimer 218

11.3.8 Sources 2191.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14

Table 3: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 21

Table 4: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 22

Table 5: Prostate Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2001-2009 24

Table 6: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2001-2009 25

Table 7: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 29

Table 8: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 30

Table 9: Prostate Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2009-2020 31

Table 10: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2009-2020 33

Table 11: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 37

Table 12: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 37

Table 13: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 39

Table 14: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 39

Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 42

Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 43

Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 44

Table 18: Prostate Cancer, Spain, Benchmarking Major Marketed Products, 2010 48

Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 54

Table 20: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 61

Table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 62

Table 22: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 63

Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 91

Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 93

Table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 93

Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 114

Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 116

Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 119

Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 128

Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 138

Table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 139

Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 194

Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 195

Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 2051.2

List of FiguresFigure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 20

Figure 2: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 21

Figure 3: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 22

Figure 4: Prostate Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2001-2009 23

Figure 5: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2001-2009 25

Figure 6: Prostate Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 27

Figure 7: Prostate Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010 28

Figure 8: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 29

Figure 9: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 30

Figure 10: Prostate Cancer Therapeutics Market, Spain, Patient Volume ('000s), 2009-2020 31

Figure 11: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns ('000s), 2009-2020 33

Figure 12: Prostate Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2009-2020 35

Figure 13: Prostate Cancer Therapeutics Market, Spain, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 36

Figure 14: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 38

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 45

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 46

Figure 17: Prostate Cancer Therapeutics Market, Spain, Sales Forecast by Therapies, 2001-2020 47

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 49

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 51

Figure 20: Prostate Cancer, Spain, Taxotere, Sales ($m), 2004-2020 52

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 53

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 57

Figure 23: Prostate Cancer, Spain, Casodex, Sales ($m), 1995-2020 58

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 59

Figure 25: Prostate Cancer, Spain, Zoladex, Sales Forecast ($m), 1998-2020 60

Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 61

Figure 27: Prostate Cancer, Spain, Leuprolide (Eligard), Sales Forecast ($m), 2005-2020 64

Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 65

Figure 29: Prostate Cancer, Spain, Firmagon, Sales Forecast ($m), 2009-2020 67

Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 68

Figure 31: Prostate Cancer, Spain, Mitoxantrone, Sales Forecast ($m), 2001-2020 70

Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 70

Figure 33: Prostate Cancer, Spain, Estramustine, Sales Forecast ($m), 2001-2020 71

Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 72

Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 73

Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 75

Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 77

Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 78

Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 79

Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 80

Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 81

Figure 42: Prostate Cancer, Spain, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 82

Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 83

Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 84

Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 85

Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 86

Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 87

Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 89

Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 92

Figure 50: Prostate Cancer, Spain, Provenge, Sales Forecast ($m), 2012-2020 96

Figure 51: Prostate Cancer, Spain, Jevtana, Sales Forecast ($m), 2011-2020 98

Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 99

Figure 53: Prostate Cancer, Spain, Aflibercept, Sales Forecast ($m), 2014-2020 101

Figure 54: Prostate Cancer, Spain, Ipilimumab , Sales Forecast ($m), 2014-2020 103

Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 104

Figure 56: Prostate Cancer, Spain, Abiraterone, Sales Forecast ($m), 2013-2020 106

Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 107

Figure 58: Prostate Cancer, Spain, Zibotentan , Sales Forecast ($m), 2013-2020 109

Figure 59: Prostate Cancer, Spain, Sprycel , Sales Forecast ($m), 2013-2020 110

Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 111

Figure 61: Prostate Cancer, Spain, MDV3100 , Sales Forecast ($m), 2013-2020 113

Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 131

Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 132

Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 132

Figure 65: Prostate Cancer, Spain, Prostate Cancer, Opportunity and Unmet Need, 2010 133

Figure 66: Prostate Cancer, Spain, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 136

Figure 67: Prostate Cancer, Spain, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 137

Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 140

Figure 69: Prostate Cancer, Spain, Implications for Future Market Competition, 2010 141

Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 143

Figure 71: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 144

Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 145

Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 146

Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 151

Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 153

Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 159

Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 160

Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 162

Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 163

Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 167

Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 167

Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 168

Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 169

Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 170

Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 175

Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 176

Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 177

Figure 88: Prostate Cancer, Global, Takeda Pharmaceuticals, SWOT Analysis 2010 181

Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 183

Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 188

Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 194

Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 197

Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 203

Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 204

Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 209

Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 210

Figure 97: Prostate Cancer, Spain, Key Data Inputs from KOL Interviews, July 2010 211

Figure 99: GlobalData Market Forecasting Model 217

Companies mentioned Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:Drug and Medication Industry: Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):